Physician profile
Lynora Curtis
NPI 1730365099
$1,911.23
in general payments reported to CMS, 2019-2025
19 companies · $637 in 2025
The $637 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $338 · 2020: $463 · 2021: $189 · 2022: $69.23 · 2023: $118 · 2024: $96.52 · 2025: $637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $772 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $772.34 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $308.72 | 2020 | |
| Sun Pharmaceutical Industries INC. | $219.07 | 2019-2025 | |
| Abbvie INC. | $210.17 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $195.22 | 2019-2025 | |
| Galderma Laboratories, L.P. | $144.88 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $130.89 | 2019-2025 | Libtayo |
| Genzyme Corporation | $115.71 | 2019-2025 | |
| Janssen Biotech, INC. | $100.38 | 2021-2025 | Tremfya |
| Pfizer INC. | $89.09 | 2021-2023 | |
| Incyte Corporation | $72.32 | 2023-2025 | Opzelura |
| Pierre Fabre Pharmaceuticals, INC. | $66.74 | 2019-2021 | |
| Biofrontera INC. | $47.96 | 2019-2025 | Ameluz |
| Arcutis Biotherapeutics, INC. | $42.14 | 2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $37.55 | 2023-2024 | Arazlo, Jublia, Cabtreo |
| Lilly USA, LLC | $36.46 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $28.79 | 2023 | Puraply |
| Organon LLC | $27.86 | 2025 | |
| Ucb, INC. | $18.86 | 2025 | Bimzelx |
| Dermavant Sciences, INC. | $18.42 | 2024 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynora Curtis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.